Data as of Jul 22
| +0.25 / +0.71%|
The 7 analysts offering 12-month price forecasts for Haemonetics Corp have a median target of 36.00, with a high estimate of 41.00 and a low estimate of 30.00. The median estimate represents a +2.01% increase from the last price of 35.29.
The current consensus among 12 polled investment analysts is to Hold stock in Haemonetics Corp. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.